TP53 and acute myeloid leukemia: Early clinical signals were observed in hematologic cancers, particularly acute myeloid leukemia (AML), where the proliferative nature of hematopoietic cells and their reliance on MDM2–p53 regulation suggested heightened sensitivity (Daver et al., 2023).